Financial Comparison: SI-Bone (SIBN) & Alliqua Biomedical (ALQA)

SI-Bone (NASDAQ:SIBN) and Alliqua Biomedical (NASDAQ:ALQA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, risk and valuation.

Insider & Institutional Ownership

39.5% of SI-Bone shares are owned by institutional investors. Comparatively, 13.9% of Alliqua Biomedical shares are owned by institutional investors. 13.2% of Alliqua Biomedical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares SI-Bone and Alliqua Biomedical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
SI-Bone N/A N/A N/A
Alliqua Biomedical N/A -72.84% -41.48%

Analyst Recommendations

This is a summary of recent ratings and target prices for SI-Bone and Alliqua Biomedical, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SI-Bone 0 0 4 0 3.00
Alliqua Biomedical 0 1 0 0 2.00

SI-Bone currently has a consensus target price of $24.75, suggesting a potential upside of 40.39%. Given SI-Bone’s stronger consensus rating and higher possible upside, analysts plainly believe SI-Bone is more favorable than Alliqua Biomedical.

Earnings & Valuation

This table compares SI-Bone and Alliqua Biomedical’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
SI-Bone $55.38 million 7.75 -$17.45 million ($0.71) -24.83
Alliqua Biomedical $2.22 million 6.31 -$8.42 million ($6.49) -0.43

Alliqua Biomedical has lower revenue, but higher earnings than SI-Bone. SI-Bone is trading at a lower price-to-earnings ratio than Alliqua Biomedical, indicating that it is currently the more affordable of the two stocks.

Summary

SI-Bone beats Alliqua Biomedical on 9 of the 12 factors compared between the two stocks.

About SI-Bone

SI-BONE, Inc., a medical device company, develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. It offers iFuse, an implant system to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. The company was founded in 2008 and is headquartered in Santa Clara, California.

About Alliqua Biomedical

Alliqua BioMedical, Inc., a regenerative technologies company, commercializes regenerative medical products that assist the body in the repair or replacement of soft tissue. The company markets MIST Ultrasound Healing Therapy, a painless noncontact low-frequency ultrasound to promote healing; and Biovance Amniotic Membrane Allograft and Interfyl Human Connective Tissue Matrix, which are human biologic regenerative technologies. It also provides contract manufacturing services, including the development, manufacture, and marketing of high water content, electron beam cross-linked, and aqueous polymer hydrogels or gels used in wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company is headquartered in Yardley, Pennsylvania.

Receive News & Ratings for SI-Bone Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SI-Bone and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit